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Antibodies against Epstein-Barr 
nuclear antigen (EBNA) in multiple 
sclerosis CSG and two pentapepfide 
seauence identities between EBNA 
A 
and myelin basic protein 
Patrick F. Bray, MD; J. Luka, PhD; Paul F. Bray, MD; K.W. Culp, BS; and J.P. Schlight, BS 
Article abstract-The Epstein-Barr virus (EBV) causes infectious mononucleosis and is linked to several disparate 
malignancies. Prior studies on patients with multiple’ sclerosis (MS) showed that 100% are EBV-seropositive and that 
their blood contains higher antibody titers than those of controls to both transformation and lytic cycle antigens. We 
performed three different assays for antibodies in CSF to three major EBV antigens from patients with MS and con- 
trols. Among 93 patients with MS, 79 (85%) had CSF that reacted with a 70 kD protein, shown to be the nuclear anti- 
gen, EBNA-1, whereas only 11 (13%) of 81 EBV-seropositive controls reacted, p < 0.001. The CSF of all 14 MS patients, 
unreactive on immunoblots, contained oligoclonal bands on agarose electrophoresis. Together, the two techniques 
exhibit 100% sensitivity in the confirmatory diagnosis of MS. We also performed amino acid searches of the Protein 
Identification Resource sequence database for protein homologies to EBNA. Two pentapeptide identities were found 
between EBNA-1 and myelin basic protein: QKRPS and PRHRD. None of more than 32,000 other proteins in the 
database contained both pentapeptides. In healthy EBV-seropositive persons, the EBV-specific, MHC-restricted T lym- 
phocytes keep the EBV-containing B lymphocytes locked in the transformed state. However, in the host genetically 
susceptible to MS, the same population of lymphocytes might recognize and interact with either of the two identified 
pentapeptides, inadvertently damaging MBP. 
NEUROLOGY 1992;42:1798-1804 
Burkitt’s original epidemiologic observations sug- 
gested a role for an infectious agent in the patho- 
genesis of the jaw tumor, Burkitt’s lymphoma 
(BL), which affects children living in the endemic 
malaria belt of central Africa.l Epstein et a12 first 
observed the virus with the electron microscope in 
tumor cells cultured from pat ients  with BL. 
Subsequently, Henle et a13 and Niederman et a1,4 
using vigilant clinical observations and extensive 
seroepidemiologic methods, showed t h a t  the 
Epstein-Barr  virus  (EBV) causes infectious 
mononucleosis. Worldwide studies have shown 
that all biopsies from undifferentiated nasopha- 
ryngeal carcinoma tumor cells contain EBV DNA 
in varying q ~ a n t i t i e s . ~  The critical role of host 
immune mechanisms in responding to a n  EBV 
infection is dramatically exemplified by the EBV- 
associated diseases in humans, including lympho- 
proliferative disorders i n  pat ients  who a re  
immunosuppressed therapeutically,6 opportunisti- 
 ally,^ or genetically.s 
Multiple sclerosis (MS), the most common pro- 
gressive demyelinating disease in the economically 
privileged western world, has been recognized as a 
clinicopathologic entity for more than 150 years. 
The cause and pathogenesis remain unclear, but 
one finds a consensus that abnormalities in both 
humoral and cellular immunity occur consistently. 
Kurtzkeg and Kurtzke and HyllestedlO have car- 
ried out extensive epidemiologic studies, including 
(1) planetary incidence and prevalence surveys, (2) 
prevalence of MS in migrants, and (3) epidemics in 
the Faroe Islands and Iceland. They have suggest- 
ed that  one or more environmental factors may 
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influence pathogenesis;  Kurtzkeg has s ta ted ,  “If 
these findings (epidemics among the Faroese and 
Icelanders) are valid, both would indicate the defi- 
nition of MS as not only an acquired disease bu t  
also a transmittable one.” However, despite years of 
effort to incriminate a causal environmental factor, 
no agent has been recovered consistently from, or 
seen in, affected CNS tissue. Nor has the  disease 
ever been transmitted to experimental animals. 
Using seroepidemiologic data, Sumaya  et all1 
were  among  the first t o  suggest an association 
between MS and EBV infection. Later, we assayed 
blood samples from MS subjects and  controls, mea- 
suring seropositivity rates and antibody concentra- 
tions to  seven common viruses.12 Comparing MS 
and control populations, we found a highly signifi- 
cant difference only for EBV. MS patients showed 
100% seropositivity compared with 89% for age- 
and sex-matched controls ( p  < 0.0001).13 S e r u m  
antibody titers against viral capsid antigen (VCA) 
were five t o  six times higher, a n d  against the 
nuclear antigen (EBNA) they were three to four 
times higher, at the same level of statistical signifi- 
cance ( p  < 0.0001).13J4 
Recently, we observed five patients with a neuro- 
logically complicated pr imary  EBV infection, in 
whom four (followed from 4 to 12 years) developed 
MS, and one had acute  disseminated encephalo- 
myelitis that left her, after a 2-year follow-up, with 
permanent neurologic deficits. l5 
The association between EBV blood seropositivi- 
ty and MS, along with the  aforementioned clinical 
association between pr imary EBV infection and 
demyelinat ing disease, prompted us t o  conduct 
studies on the CSF of MS and control patients. We 
performed assays of antibodies against the latency- 
associated antigen, EBNA, and against the lytic 
cycle antigens, VCA a n d  ea r ly  ant igen-diffuse 
(EA-D), in M S  and neurologic d isease  controls  
(NDC). We also carried out searches for amino acid 
sequence identities between myelin basic protein 
(MBP) and all other proteins listed in a national 
protein sequence database. 
Methods. Clinical patient selection. The diagnosis and 
available laboratory findings were individually reviewed 
in a group of 246 patients. A neurologic or neuropsychi- 
atric diagnosis was under consideration in all these 
patients, and so a CSF examination was performed. MS 
patients were included in the study only if two or more 
neurologists considered the diagnosis clinically definite. 
A clinical diagnosis of MS was made only if the neurolog- 
ic disorder met standard criteria.16J7 Confirmatory tests 
included the established methods for immunoglobulin 
analysis and brain imaging procedures. No patient was 
included in the study unless the blood-brain barrier 
(BBB) was intact, as determined by the ratio of CSF 
albumidserum albumin. l8 
Each NDC patient received the same clinical and lab- 
oratory scrutiny. Subjects were included in this category 
only if their serum EBV antibody profile was positive, if 
they had an intact BBB, and if demyelinating disease 
was excluded. The diagnostic spectrum of this group 
ranged from patients with stroke, progressive nonde- 
myelinating degenerative disorders, psychiatric disor- 
ders, tumor, and infectious-inflammatory diseases, 
excluding known primary EBV infections, to any patient 
who presented with complaints referable to  the nervous 
system and in whom the neurologist considered a CSF 
examination advisable. 
Laboratory techniques. Quantitative and qualitative 
analyses of CSF k G .  Approximately 95% of patients 
with the diagnosis of clinically definite MS exhibit an 
increased CNS synthesis of IgG or the presence of oligo- 
clonal bands (OCB) in their CSF.19 OCB were identified 
by agarose gel electrophoresis.20 
Cell lines. We used several cell lines as sources for the 
different EBV viral antigens. The BL-derived, non-virus- 
producing Raji cell line carries the EBV genome and is 
known to express EBNA-1 constitutively.z1 The virus- 
producing line, P3HR1, was used as a source of VCA.z2 
Raji cells superinfected with virus produced from the 
P3HR1 cell line were used as a source for expression of 
EA-D protein.zz An EBV-genome-negative BL cell line, 
designated BJAB, was used as a negative control. 
Anticomdement immunofluorescence (ACIF). Using 
P3HR1 cells, we employed serial dilutions of CSF to 
identify antibodies to  VCA, as described 
Enzyme-linked immunosorbent assays (EIA). EIAs 
were performed using purified EBV EBNA-IgG proteinz3 
and purified EBV VCA-IgG protein22-26 (generously pro- 
vided by Ortho Diagnostics Systems, Inc.) as target anti- 
gens and CSF as  the antibody source. Methodologic 
details were performed according to the manufacturer’s 
instructions. Preliminary experiments revealed that a 
1: 10 dilution distinguished best between background 
activity and specific antibody in both control and MS 
CSF samples. 
Western immunoblots. P3HR1, Raji, and BJAB cells 
were washed in phosphate-buffered saline, which is 
0.136 M NaC1, 2.68 mM KC1, 10 mM Na,HPO,, and 1.76 
mM KH,PO,, pH 7.4. Cells were solubilized in 2% sodi- 
um dodecyl sulfate (SDS), and 15 bg of protein was sepa- 
rated by SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) and transferred t o  nitrocellulose sheets.27 The 
sheets were cut into strips and incubated with individual 
CSF samples as the primary antibody in a final volume 
of 0.6 ml. The amount of IgG in each CSF sample was 
standardized to IgG 1.0 mg/dl in 0.5% bovine serum 
albumin/0.05% Tween-20 in phosphate-buffered saline. 
Control sera came from individuals with high-titer anti- 
bodies to  EBNA-1, as assayed by ACIF. In some experi- 
ments, a monoclonal antibody specific for the EA-D anti- 
gen was used a s  the  primary antibody in the im- 
munoblots.22 
Analyses on the 70 kD protein. Cell extracts for 
immunoblotting and peptide mapping were performed by 
sonicating 2 X lo8 Raji cells in a buffer containing 150 
mM NaC1, 20 mM TRIS-HC1, pH 7.4, 10 mM NaF, 1 mM 
phenyl methyl sulfonyl fluoride, and 1 mM P-mercapto- 
ethanol. The extract was clarified by centrifugation in a 
Sorvall centrifuge at  20,000 x g for 1 hour. The super- 
natant was removed from the pellet and was heat-treat- 
ed at  70 “C for 10 minutes to precipitate heat-labile pro- 
teins. Then the heat-precipitated proteins were pelleted 
at  10,000 X g for 15 minutes. The supernatant was used 
in SDS-PAGE for immunoblotting, either without further 
t reatment  o r  af ter  incubation with 10 pg/ml chy- 
motrypsin (Sigma, Type VII-TLCK treated) at  37 “C for 
12 hours. 
Protein sequence homologies between EBNA-1 and 
human mvelin basic motein. Using the FASTA program, 
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we searched the Protein Identification Resource (PIR) 
sequence database, version 29.0, for amino acid sequence 
identities between MBP and all other proteins of defined 
sequence.28 
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Results (figure 1). Anti-EBNA-1 IgG CSF antibod- 
ies (EIA and immunoblots). To identify possible 
anti-EBV antibodies in CSF samples, we performed 
EIAs, using purified EBNA-1 protein as the target 
antigen. 
Using Ortho’s high-titer positive and negative 
serum controls,.we measured antibodies to EBNA-1 
and VCA in  the  study and control populations. 
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Figure 1. Summary of Epstein-Burr virus CSF antibody 
data in patients with multiple sclerosis and neurologic 
disease controls. 
Among the MS patients, 35 of 50 (70%) of the CSF 
samples were EIA-positive compared with eight of 
50 (16%) NDC, results that  differed significantly: x2 
= 29.74, df 1, p c 0.001 (figure 1). These results 
suggested the presence of a protein in the CSF of 
patients with MS that  reacted with the EBNA-1 
protein in this assay. 
To rule out the possibility of a contaminating 
immunoreactive, non-EBNA-1 antigen in the EIAs, 
we then performed Western immunoblots on both 
untreated and heat-treated Raji cell extracts using 
whole CSF as the primary source of antibody. An 
additional group of 174 MS and NDC patients was 
studied. The results of the CSF immunoblot analy- 
ses from these patients are also summarized in fig- 
ure 1. Among the CSF samples from patients with 
MS, 79 of 93 (85%) exhibited a 70 kD protein, and 
14 of 93 (15%) were negative. Seventy of 81 (87%) 
NDC samples were unreactive, and 11 of 81 (13%) 
did react. 
A typical sampling of these results is seen in fig- 
ure 2. Lanes A and B contain sera from healthy con- 
trols, which reacted with a 70 kD protein. Five of 
the 10 CSF samples, all from patients with the clin- 
ical  diagnosis of MS, also reacted with a co- 
migrating 70 kD protein (lanes C, D, F, G, and K). 
The CSF from five NDC (lanes E, H, I, L, and M) 
did not react. These results support the findings of 
the EIA, indicating that this antibody in the CSF 
reacts with a heat-stable protein. EBNA-1 is known 
to migrate with a Mr-70 kD protein in SDS-PAGE. 
To rule out the possibility of a coincidentally co- 
migrating protein, we sought supporting evidence 
that  the 70 kD protein was, in fact, EBNA-1. We 
Figure 2. Immunoblots of 
heat-treated Raji cell 
lysates with CSF samples 
and control sera. Cell 
extracts were applied to 
an 8% sodium dodecyl 
sulfate-polyacrylamide 
gel, electrophoresed, and 
transferred to Immobilin 
Ppaper. The strips were 
exposed to anti- 
EBNA-positive human 
serum (lanes A and B) 
and to various CSF 
samples (lanes B through 
M). The 70 kD protein is 
indicated by the arrow. 
Samples from patients 
with multiple sclerosis 
are shown in lanes C, D, 
F, G, and K. Neurologic 
disease control samples 
appear in lanes E, H, I, 
L, and M .  
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Figure 3. Immunoblots of heat-treated and chymotrypsin- 
digested Raji cell extracts. Treated extracts were applied 
to a 10% sodium dodecyl sulfate polyacrylamide gel, 
electrophoresed, and transferred to Immobilin P paper. 
The 40 kD peptide is indicated by the arrow. The serums 
and CSF samples are identical with and appear in the 
same alphabetized lane sequence as those shown in figure 
2. 
incubated the Raji cell extracts with chymotrypsin 
to determine a limited peptide map of the 70 kD 
protein. Figure 3 shows the results obtained when 
CSF was reacted with these digested Raji cell 
extracts. As in figure 2, the same two positive sera 
and five MS CSF samples reacted, but with a 
smaller peptide of Mr-40 kD. The NDC, as in fig- 
ure 2, did not identify this fragment. 
Anti-VCA CSF IgG antibody (ACIF and EIA). 
Previous work by us, using the Raji cell line, has 
shown that the VCA antigen (160 kD) cannot be 
detected by Western blotting (unpublished observa- 
tions). In the standard serum assay for identifica- 
tion of anti-VCA antibodies, ACIF is performed on 
P3HR1 cells. We modified this procedure by using 
CSF as the antibody source. Antibodies to VCA 
were present in 32 of 47 (68%) MS CSF samples 
and in 12 of 55 (22%) NDC (figure 1). Geometric 
mean titers of anti-VCA from 77 patients with MS 
and 41 NDC, respectively, were 2.79 compared 
with 1.41 in CSF, and 292 compared with 218 in 
serum. The two groups differed statistically but the 
absolute differences were small: CSF x2 = 22, d f  3, p 
< 0.001; serum x2 = 18.5, df 44, p < 0.001. The BBB 
had no influence on the statistically higher concen- 
trations in the MS population: r = 0.00 (Pearson’s 
correlation coeffi~ient) .~~ 
Figure 1 shows that on EIA, 24 of 50 (48%) MS 
CSF samples contained anti-VCA antibodies com- 
pared with 14 of 50 (28%) NDC tha t  exhibited 
seropositivity, results that  differed slightly from 
one another: x2 = 4.24, 1 d f ,  p < 0.05. 
Anti-EA-D antibody (immunoblots and ACIF). 
To detect antibodies against the EA-D antigen, we 
probed superinfected Raji cells by using CSF on 
Western blots, as above. A monoclonal antibody 
specific for EA-D was used to  identify its position 
on the filter. We studied 50 additional CSF speci- 
mens, 26 samples from MS and 24 from NDC 
patients.The CSF from one patient with MS and 
two NDC patients reacted with a peptide tha t  
comigrated with the protein identified by the mono- 
clonal anti-EA-D antibody (figure l) ,  findings that 
appear insignificantly different. 
ACIF has been performed on 177 CSF speci- 
mens, mostly from MS and NDC patients. EA-D 
was measurable in only one sample, from a patient 
with a primary T-cell brain lymphoma (unpub- 
lished observations). 
CSF OCB and immunoblot data. Of note is that 
all 14 MS patients who lacked antibodies in their 
CSF to EBNA-1 on immunoblot assays demonstrat- 
ed CSF IgG OCB on agarose electrophoresis. By 
contrast, the 11 NDC patients who were anti- 
EBNA antibody-positive had normal CSF quantita- 
tive and qualitative IgG. No obvious clinical differ- 
ences in the 14 MS patients whose CSF was anti- 
EBNA-negative were found when compared with 
the MS population as a whole. We conclude that, in 
this study, by applying a combination of agarose 
electrophoresis and immunoblotting, we have been 
able to identify 100% of MS patients. 
Protein sequence identities between EBNA-1 and 
MBP. The finding of an anti-EBNA-1 antibody in 
the CSF of 85% of our patients with MS led us to  
ask  whether any protein similarities existed 
between EBNA-1 and MBP in view of the fact that 
the latter is conspicuously lost or damaged in the 
CNS of patients with MS. We used the FASTA pro- 
gram to search the PIR sequence database for iden- 
tities (see Methods). Short identical matches were 
found for two separate five-amino-acid sequences 
between EBNA-1, a protein containing 641 amino 
acids, and human MBP, a protein containing 169 
amino acids. Using the conventional one-letter 
amino acid code,30 we found two separate penta- 
peptides, QKRPS and PRHRD. QKRPS corre- 
sponds to published amino acid positions 74 to 78 
in EBNA-1 and 3 to  7 in MBP. PRHRD corresponds 
t o  published amino acid positions 64 to 68 in 
EBNA-1 and 30 to 34 in MBP.31,32 
The FASTA program was then used to  search 
the PIR database for amino acid sequences contain- 
ing both QKRPS and PRHRD. Among approxi- 
mately 32,000 proteins in  the database, only 
EBNA-1 and MBP contained both sequences. 
Discussion. Our data show t h a t  the  CSF of 
patients with MS, when compared with controls, 
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contains excessive amounts of antibodies directed 
against EBNA-1. Several lines of evidence indicate 
that  these antibodies are specific for EBNA-1. 
First, elevated anti-EBNA-1 titers in the CSF were 
detected in an EIA using purified EBNA-1 as the 
target antigen. Second, CSF reacts with a 70 kD 
protein on Western blots of Raji cells, which are 
known to express EBNA-1, and 70 kD is the expect- 
ed Mr of EBNA-1.22 Unlike over 80% of the cellular 
proteins that are heat-aggregated at 70°C, EBNA-1 
remains soluble at this t e m p e r a t ~ r e , ~ ~  as does the 
peptide we have identified on Western immuno- 
blots. Third, Hennessy and KiefP4 have shown that 
EBNA-1 contains a domain that includes a glycine- 
alanine copolymer. Although this region cannot be 
cut or digested by many proteases (personal obser- 
vations, J. Luka), digestion by chymotrypsin yields 
a 40 kD immunoreactive fragment containing the 
glycine-alanine copolymer typical of EBNA-1 in 
Raji cells. The unique glycine-alanine repeating 
sequence migrates as a -40 kD peptide on SDS- 
PAGE and will react with anti-EBNA-1 positive 
sera. I t  has been shown in the general population 
that nearly 100% of the anti-EBNA antibody-posi- 
tive human sera recognize this domain, so this pro- 
teolytic cleavage fragment can be used for identifi- 
cation of anti-EBNA-1 a n t i b o d i e ~ . ~ ~  When chy- 
motrypsin was used to digest the Raji cell extracts, 
the CSF samples from patients with MS reacted 
with a 40 kD peptide. Taken together, these data 
strongly support  the  presence of excessive 
anti-EBNA-1 antibody in the CSF from patients 
with MS. 
The results presented in this report can be 
viewed arbitrarily from two vantage points-one 
with a view toward possible mechanisms involved 
in the pathogenesis of MS and one with minor diag- 
nostic implications. 
For more than a generation, many investigators 
studying MS have been devoted to the idea that 
demyelination results from an autoimmune pro- 
cess. Several lines of evidence support this belief. 
First, the classic animal model for T-cell-mediated 
autoimmune disease, experimental  allergic 
encephalomyelitis (EAE), has an almost identical 
histopathologic resemblance to MS. However, there 
are crucial differences between EAE and MS. The 
former is an artificially induced paralytic disorder 
that develops in animals that have been injected 
with a major protein constituent of myelin, where- 
as MS is a naturally occurring disease of humans 
in which genetic and environmental factors are 
incompletely understood. Second, at  least 13 differ- 
ent viruses share limited amino acid sequence 
homology with human MBP.36,37 Third, within the 
past few years a series of  report^^^-^^ has shown 
that T cells isolated from. MS patients react with 
restricted synthetic peptides derived from the MBP 
sequence. These observations, along with the abili- 
ty of T cells taken from animals with EAE to pre- 
vent or reverse EAE by vaccination of unaffected 
animals, have reinforced the suspicion that T lym- 
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phocytes play an essential role in the process of 
demyel ina t i~n .~~ Precisely how the demyelination 
process is set in motion is still unclear. 
Although it is possible, but unlikely, that the 
anti-EBNA-1 specific antibodies are involved in 
the pathogenesis of MS, our finding of amino acid 
sequence identities between EBNA-1 and MBP 
suggests a mechanism compatible with the central 
role of the T lymphocyte. It has been reported by 
Zamvil e t  a143 that a nine-amino-acid residue of 
murinehuman MBP is required to induce EAE. Of 
particular interest in the latter study is that the 
EBNA-1 pentapeptide, QKRPS, is contained within 
the nine-amino-acid sequence identified in the 
encephalitogenic epitope of MBP. 
Ota et a141 were unable to demonstrate that a 
peptide containing the first 20 residues of MBP 
induced reactivity in T-cell clones responsive to  the 
entire MBP protein. Although we have no conflict- 
ing data, we can postulate several possible expla- 
nations of why the QKRPS sequence could be 
pathogenic. First, a synthetic 20-amino-acid pep- 
tide from this region may not assume the same sec- 
ondary and  te r t ia ry  s t ructure  a s  the  native 
molecule. Second, the in  vitro manipulations 
required to generate T-cell clones reactive to MBP 
may not reflect an accurate representation of the in 
vivo response. Third, as pointed out by Zamvil et 
al,43 production of EAE in the mouse requires the 
acetylation of the amino terminus of the peptide 
containing residues 1 to 9 of MBP. Ota et a1 did not 
describe this acetylation modification in the first 
20-amino-acid residue they synthesized from 
MBP.41 Fourth, the highly basic region of EBNA-1 
could conceivably induce charge-dependent cross- 
reaction to MBP. Finally, it is not unreasonable to  
speculate that a heterogeneous group of molecular 
defects causes the MS phenotype. 
Our observation of modest elevations in both 
blood and CSF anti-VCA antibodies may be rele- 
vant in the light of Rickinson's in vitro studies44 of 
EBV-transformed B cells. He and his coworkers 
have shown that although most B cells remain per- 
manently locked in the transformation cycle, a 
small percentage of cells enters the lytic cycle, 
releasing virus particles. If this mechanism occurs 
in vivo, one would expect the production of anti- 
VCA antibody. 
The diagnosis of MS remains clinical because no 
specific laboratory test has yet been developed. 
Nevertheless, it is now known that approximately 
95% of patients with MS exhibit an increased quan- 
tity or an abnormal quality (OCB) of IgG in their 
CSF on agarose gel electrophoresis, the simplest 
technique for the routine diagnostic laboratory. The 
authors readily acknowledge that qualitative IgG 
changes may be demonstrable in almost 100% of 
MS CSF if SDS-PAGE or sensitive immunofixation 
techniques,  ra ther  t han  agarose, a re  used. 
However, our experience at  this time convinces us 
tha t  these more sensitive methods, as well as  
Western blots, require interpretation by an expert 
devoted to  the study of CSF immunoglobulins. 
As a rule, in healthy EBV-seropositive persons, 
the EBV-specific, class 11, MHC-restricted T lym- 
phocytes keep the EBV-genome-containing B cells 
locked in the transformed state. However, in the 
host genetically susceptible to  MS, the same popu- 
lation of T cells could recognize and interact with 
either of the highly charged epitopes, QKRPS or 
PRHRD, inadvertently damaging MBP. Further 
studies will be required to address this hypothesis. 
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